{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:05:07Z","timestamp":1773273907625,"version":"3.50.1"},"reference-count":55,"publisher":"Informa UK Limited","issue":"2","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1080\/13543784.2026.2627204","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T11:48:33Z","timestamp":1770119313000},"page":"121-131","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Progress of investigational bromodomain and extra-terminal domain inhibitors for myelofibrosis therapy"],"prefix":"10.1080","volume":"35","author":[{"given":"Nooshin C.","family":"Beygui","sequence":"first","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai","place":["New York, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Rogers","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai","place":["New York, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veer","family":"Shah","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai","place":["New York, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6718-2974","authenticated-orcid":false,"given":"Megan","family":"Metzger","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai","place":["New York, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Mascarenhas","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai","place":["New York, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2026,2,9]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.1992756"},{"key":"e_1_3_5_4_1","unstructured":"Llobet-Canella M. Review | Biology diagnosis and treatment of myelofibrosis up to date. MPN Hub; [cited 2025 May 21]. Available from: https:\/\/mpn-hub.com\/medical-information\/review-or-biology-diagnosis-and-treatment-of-myelofibrosis-up-to-date"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01767-y"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-024-00744-9"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-3099-2"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/sigtrans.2017.23"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M410994200"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.9490"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.11.009"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26857"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0107-z"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2019.317"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-020-00596-z"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.115840"},{"key":"e_1_3_5_17_1","unstructured":"Study details | Controlled myelofibrosis study with oral JAK inhibitor treatment: the COMFORT-I trial | ClinicalTrials.Gov. [cited 2025 Jun 19]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT00952289#publications"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01972"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(24)00212-6"},{"key":"e_1_3_5_20_1","unstructured":"Celgene. A phase 3b multicenter single-arm open-label efficacy and safety study of fedratinib in subjects with DIPSS (dynamic international prognostic scoring system)-intermediate or high-risk primary myelofibrosis (PMF) post-polycythemia vera myelofibrosis (post-PV MF) or post-essential thrombocythemia myelofibrosis (post-ET MF) and previously treated with ruxolitinib. clinicaltrials.gov. 2024 [cited 2025 Jul 16]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03755518"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1411972"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02036-0"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.5818"},{"key":"e_1_3_5_24_1","unstructured":"CTI BioPharma. A randomized controlled phase 3 study of oral pacritinib versus best available therapy in patients with primary myelofibrosis post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis. clinicaltrials.gov. 2020 [cited 2025 Jul 26]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT01773187"},{"key":"e_1_3_5_25_1","unstructured":"CTI BioPharma. A randomized controlled phase 3 study of oral pacritinib versus best available therapy in patients with thrombocytopenia and primary myelofibrosis post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis. clinicaltrials.gov. 2021 [cited 2025 Jul 26]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02055781"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13855"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01647-6"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41580-021-00441-y"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature09504"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41580-018-0081-3"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2021.12.004"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.728777"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/wrna.1734"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaz8455"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.260"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/med.21942"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.CRC-22-0060"},{"key":"e_1_3_5_38_1","unstructured":"Constellation Pharmaceuticals. A phase 2 study of CPI-0610 a small molecule inhibitor of BET proteins: phase 1 (dose escalation of CPI-0610 in patients with hematological malignancies) and phase 2 (dose expansion of CPI-0610 with and without ruxolitinib in patients with myelofibrosis and essential thrombocytopenia). clinicaltrials.gov. 2025 [cited 2025 May 26]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02158858"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2023.2300710"},{"key":"e_1_3_5_40_1","unstructured":"Constellation Pharmaceuticals. A phase 3 randomized double-blind active-control study of pelabresib (CPI-0610) and ruxolitinib vs. placebo and ruxolitinib in JAKi treatment naive MF patients. clinicaltrials.gov. 2024 [cited 2025 Jul 21]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04603495"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-193193"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03572-3"},{"key":"e_1_3_5_43_1","unstructured":"Vannucchi A Rampal R Chraniuk D et al. Pelabresib in combination with ruxolitinib for janus kinase inhibitor-naive patients with myelofibrosis: 72-week follow-up with long-term efficacy outcomes of the phase III manifest-2 study. European Hematology Association; 2025 May 14 [cited 2025 Sep 28]. Available from: https:\/\/library.ehaweb.org\/eha\/2025\/eha2025-congress\/4159300\/alessandro.vannucchi.pelabresib.in.combination.with.ruxolitinib.for.janus.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D2%2Asearch%3Ds223"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-137686"},{"key":"e_1_3_5_45_1","unstructured":"Safety and tolerability study of oral ABBV-744 tablet alone or in combination with oral ruxolitinib tablet or oral navitoclax tablet in adult participants with myelofibrosis. [cited 2025 May 26]. Available from: https:\/\/www.abbvieclinicaltrials.com\/study\/?id=M20-247"},{"key":"e_1_3_5_46_1","unstructured":"AbbVie. A phase 1b study of ABBV-744 alone or in combination with ruxolitinib or navitoclax in subjects with myelofibrosis. clinicaltrials.gov. 2024 [cited 2025 May 26]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04454658"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-179428"},{"key":"e_1_3_5_48_1","unstructured":"Incyte Corporation. A phase 1 open-label safety and tolerability study of INCB057643 in participants with myelofibrosis and other advanced myeloid neoplasms. clinicaltrials.gov. 2025 [cited 2025 May 26]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04279847"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.6574"},{"key":"e_1_3_5_50_1","unstructured":"A study to assess the safety and tolerability of BMS-986158 alone and in combination with either ruxolitinib or fedratinib in participants with blood cancer (myelofibrosis) | BMS clinical trials. [cited 2025 May 26]. Available from: https:\/\/www.bmsclinicaltrials.com\/us\/en\/clinical-trials\/NCT04817007"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-159476"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-179160"},{"key":"e_1_3_5_53_1","unstructured":"Early results from the PROMise trial reveal promising tolerability and spleen size reductions in MF. Blood Cancers Today. [cited 2025 May 26]. Available from: https:\/\/www.bloodcancerstoday.com\/post\/promise-early-results-for-combination-ruxolitinib-and-bet-inhibitor-treatment-show-promising-tolerability-and-spleen-size-reductions-in-myelofibrosis"},{"key":"e_1_3_5_54_1","unstructured":"EU Clinical Trials Register. Promise study: investigation into the combination of PLX2853 (OPN\u20112853) with ruxolitinib in patients with intermediate\u20112 or high\u2011risk myelofibrosis not receiving an adequate response to ruxolitinib alone. 2020. Available from: https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-000916-27\/GB#A"},{"key":"#cr-split#-e_1_3_5_55_1.1","unstructured":"Editor. Opna bio announces 2024 ASH presentations highlighting interim data from phase 1 combo study of BET inhibitor OPN-2853 with ruxolitinib in myelofibrosis and promising preclinical data with EP300\/CBP bromodomain inhibitor OPN-6602 in multiple myeloma. Opna Bio"},{"key":"#cr-split#-e_1_3_5_55_1.2","unstructured":"2024 Nov 13 [cited 2025 May 26]. Available from: https:\/\/www.opnabio.com\/opna-bio-announces-2024-ash-presentations-highlighting-interim-data-from-phase-1-combo-study-of-bet-inhibitor-opn-2853-with-ruxolitinib-in-myelofibrosis-and-promising-preclinical-data-with-ep300-cbp\/"},{"key":"e_1_3_5_56_1","volume-title":"Presented at: American Society of Hematology Annual Meeting","author":"Mead A","year":"2024","unstructured":"Mead A. Interim analysis of PROMise, a clinical study combining the BET inhibitor OPN\u20112853 with ruxolitinib in patients with advanced myelofibrosis experiencing an inadequate response to ruxolitinib. Presented at: American Society of Hematology Annual Meeting; San Diego, CA; 2024 Dec 8. Available from: https:\/\/www.opnabio.com\/wp-content\/uploads\/2024\/12\/PROMise-ASH-2024-Poster.pdf"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543784.2026.2627204","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T09:35:24Z","timestamp":1773221724000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543784.2026.2627204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1080\/13543784.2026.2627204"],"URL":"https:\/\/doi.org\/10.1080\/13543784.2026.2627204","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-11-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}